Related references
Note: Only part of the references are listed.Strategies for subtypes-dealing with the diversity of breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011
A. Goldhirsch et al.
ANNALS OF ONCOLOGY (2011)
Tumor Biomarker Changes Following Pre-Surgical Treatment with 500 mg Fulvestrant Plus Anastrozole Versus 500 mg Fulvestrant Alone and 1 mg Anastrozole Alone.:
J. Robertson et al.
CANCER RESEARCH (2010)
Results of the CONFIRM Phase III Trial Comparing Fulvestrant 250 mg With Fulvestrant 500 mg in Postmenopausal Women With Estrogen Receptor-Positive Advanced Breast Cancer
Angelo Di Leo et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Third consensus on medical treatment of metastatic breast cancer
S. Beslija et al.
ANNALS OF ONCOLOGY (2009)
Combination of anastrozole with fulvestrant in the intratumoral aromatase xenograft model
Luciana F. Macedo et al.
CANCER RESEARCH (2008)
Pharmacokinetic profile of the fulvestrant loading dose regimen in postmenopausal women with hormone receptor-positive advanced breast cancer
Peter McCormack et al.
CLINICAL BREAST CANCER (2008)
Emerging Biomarkers and New Understanding of Traditional Markers in Personalized Therapy for Breast Cancer
Mitch Dowsett et al.
CLINICAL CANCER RESEARCH (2008)
Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival:: an overview of the randomised trials
O Abe et al.
LANCET (2005)
Activation of mitogen-activated protein kinase in xenografts and cells during prolonged treatment with aromatase inhibitor letrozole
D Jelovac et al.
CANCER RESEARCH (2005)
Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival:: an overview of the randomised trials
O Abe et al.
LANCET (2005)
Pharmacokinetic profile of intramuscular fulvestrant in advanced breast cancer
JFR Robertson et al.
CLINICAL PHARMACOKINETICS (2004)
Phase III study of letrozole versus tamoxifen as first-line therapy of advanced breast cancer in postmenopausal women:: Analysis of survival and update of efficacy from the international letrozole breast cancer group
H Mouridsen et al.
JOURNAL OF CLINICAL ONCOLOGY (2003)
New guidelines to evaluate the response to treatment in solid tumors
F Duffaud et al.
BULLETIN DU CANCER (2000)
Anastrozole is superior to tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: Results of a North American multicenter randomized trial
JM Nabholtz et al.
JOURNAL OF CLINICAL ONCOLOGY (2000)
Anastrozole versus tamoxifen as first-line therapy for advanced breast cancer in 668 postmenopausal women:: Results of the tamoxifen or arimidex randomized group efficacy and tolerability study
J Bonneterre et al.
JOURNAL OF CLINICAL ONCOLOGY (2000)
New guidelines to evaluate the response to treatment in solid Tumors
P Therasse et al.
JOURNAL OF THE NATIONAL CANCER INSTITUTE (2000)
Share Paper
